| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(12 years from now) | |
| US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(12 years from now) | |
Dexmedetomidine Hydrochloride is owned by Hq Spclt Pharma.
Dexmedetomidine Hydrochloride contains Dexmedetomidine Hydrochloride.
Dexmedetomidine Hydrochloride has a total of 2 drug patents out of which 0 drug patents have expired.
Dexmedetomidine Hydrochloride was authorised for market use on 21 October, 2015.
Dexmedetomidine Hydrochloride is available in solution;intravenous dosage forms.
The generics of Dexmedetomidine Hydrochloride are possible to be released after 20 April, 2036.
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
DEXMEDETOMIDINE HYDROCHLORIDE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic